Ixekizumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1312 publications

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.

Journal: JAMA dermatology

Published: January 07, 2026

What is the optimal sequential therapy after secondary IL-17A inhibitor failure in psoriasis: switching to an IL-23 inhibitor or to another IL-17A inhibitor?

What is the optimal sequential therapy after secondary IL-17A inhibitor failure in psoriasis: switching to an IL-23 inhibitor or to another IL-17A inhibitor?

Journal: The Journal of dermatological treatment

Published: December 11, 2025

New Toxicity Signals Associated With Ixekizumab.

New Toxicity Signals Associated With Ixekizumab.

Journal: The Annals of pharmacotherapy

Published: December 10, 2025

Onycho-pachydermo periostitis: Ixekizumab as a therapeutic option.

Onycho-pachydermo periostitis: Ixekizumab as a therapeutic option.

Journal: JAAD case reports

Published: November 14, 2025

The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study.

The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study.

Journal: Journal of cosmetic dermatology

Published: November 13, 2025

Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes.

Design and methods of the Ixekizumab Diabetes Intervention Trial (I-DIT): protocol for a phase 2, randomised, multicentre, placebo-controlled, double-blind trial of anti-interleukin 17 as a treatment option for adults with new-onset type 1 diabetes.

Journal: BMJ open

Published: November 12, 2025

Comprehensive assessment of 5 interleukin inhibitors for the treatment of psoriasis: scientific guidance based on drug selection recommendations for Chinese medical institutions.

Comprehensive assessment of 5 interleukin inhibitors for the treatment of psoriasis: scientific guidance based on drug selection recommendations for Chinese medical institutions.

Journal: Journal of pharmaceutical policy and practice

Published: November 10, 2025

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study.

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study.

Journal: Journal of cosmetic dermatology

Published: November 05, 2025

Long-term Clinical Efficacy, Safety, and Drug Survival of Ixekizumab for Patients with Psoriasis in a Real-life Setting.

Long-term Clinical Efficacy, Safety, and Drug Survival of Ixekizumab for Patients with Psoriasis in a Real-life Setting.

Journal: Acta dermatovenerologica Croatica : ADC

Published: November 03, 2025

IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity.

IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity.

Journal: mAbs

Published: October 19, 2025

Correction to "Safety and Effectiveness of Ixekizumab in Japanese Patients with Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post-marketing Surveillance".

Correction to "Safety and Effectiveness of Ixekizumab in Japanese Patients with Psoriasis Vulgaris, Psoriatic Arthritis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis: Post-marketing Surveillance".

Journal: The Journal of dermatology

Published: October 14, 2025

Correction: Distribution of nailfold videocapillaroscopy parameters in systemic lupus erythematosus and their association with disease activity: an international blinded case-control analysis on behalf of the EULAR study group on microcirculation in rheumatic diseasesEffectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study.

Correction: Distribution of nailfold videocapillaroscopy parameters in systemic lupus erythematosus and their association with disease activity: an international blinded case-control analysis on behalf of the EULAR study group on microcirculation in rheumatic diseasesEffectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study.

Journal: RMD open

Published: October 09, 2025

Showing 1-12 of 1,312

Last Updated: 02/24/2026